1. Home
  2. SJT vs NKTX Comparison

SJT vs NKTX Comparison

Compare SJT & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SJT

San Juan Basin Royalty Trust

N/A

Current Price

$3.55

Market Cap

172.0M

Sector

Energy

ML Signal

N/A

Logo Nkarta Inc.

NKTX

Nkarta Inc.

N/A

Current Price

$2.76

Market Cap

198.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SJT
NKTX
Founded
1980
2015
Country
United States
United States
Employees
495
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
198.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SJT
NKTX
Price
$3.55
$2.76
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$11.33
AVG Volume (30 Days)
191.3K
526.7K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.41
$1.63
52 Week High
$7.00
$3.65

Technical Indicators

Market Signals
Indicator
SJT
NKTX
Relative Strength Index (RSI) 32.06 48.85
Support Level N/A $2.59
Resistance Level $5.87 $2.78
Average True Range (ATR) 0.17 0.20
MACD -0.03 -0.04
Stochastic Oscillator 16.88 44.18

Price Performance

Historical Comparison
SJT
NKTX

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: